KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Invested Capital (2024 - 2025)

Historic Return on Invested Capital for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Q3 2025 value amounting to 0.26%.

  • Acadia Pharmaceuticals' Return on Invested Capital rose 700.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.35% for FY2024, which is 5600.0% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Return on Invested Capital is 0.26%, which was up 700.0% from 0.25% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Invested Capital peaked at 0.31% during Q4 2024, and registered a low of 0.55% during Q4 2022.
  • Its 5-year average for Return on Invested Capital is 0.19%, with a median of 0.34% in 2021.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Return on Invested Capital tumbled by -2400bps in 2022, and later surged by 6500bps in 2024.
  • Acadia Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.31% in 2021, then plummeted by -78bps to 0.55% in 2022, then skyrocketed by 59bps to 0.22% in 2023, then skyrocketed by 239bps to 0.31% in 2024, then fell by -15bps to 0.26% in 2025.
  • Its Return on Invested Capital was 0.26% in Q3 2025, compared to 0.25% in Q2 2025 and 0.27% in Q1 2025.